GRC vs. ABBV
GRC (The Gorman-Rupp Company) and ABBV (AbbVie Inc.) are both stocks. GRC operates in Specialty Industrial Machinery (Industrials), while ABBV operates in Drug Manufacturers - General (Healthcare). Over the past 10 years, GRC returned 14.19%/yr vs 19.10%/yr for ABBV. At a 0.25 correlation, their price movements are largely independent.
Performance
GRC vs. ABBV - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, GRC achieves a 78.10% return, which is significantly higher than ABBV's 1.30% return. Over the past 10 years, GRC has underperformed ABBV with an annualized return of 14.19%, while ABBV has yielded a comparatively higher 19.10% annualized return.
GRC
- 1D
- 2.14%
- 1M
- 12.41%
- YTD
- 78.10%
- 6M
- 71.53%
- 1Y
- 133.46%
- 3Y*
- 48.08%
- 5Y*
- 21.07%
- 10Y*
- 14.19%
ABBV
- 1D
- 1.32%
- 1M
- 9.22%
- YTD
- 1.30%
- 6M
- 3.65%
- 1Y
- 22.21%
- 3Y*
- 22.39%
- 5Y*
- 18.94%
- 10Y*
- 19.10%
GRC vs. ABBV - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
GRC The Gorman-Rupp Company | 78.10% | 28.24% | 8.87% | 42.15% | -41.17% | 39.71% | -11.90% | 17.64% | 11.75% | 2.49% |
ABBV AbbVie Inc. | 1.30% | 33.08% | 18.86% | -0.23% | 24.01% | 32.43% | 27.72% | 1.47% | -0.96% | 60.07% |
Correlation
The correlation between GRC and ABBV is 0.19, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.19 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.16 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.18 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.23 |
Correlation (All Time) Calculated using the full available price history since Jan 2, 2013 | 0.25 |
Fundamentals
GRC:
$2.23B
ABBV:
$403.99B
GRC:
$2.23
ABBV:
$2.05
GRC:
37.88
ABBV:
110.96
GRC:
3.20
ABBV:
6.43
GRC:
2.59
ABBV:
14.69
GRC:
$695.03M
ABBV:
$62.82B
GRC:
$210.01M
ABBV:
$46.15B
GRC:
$118.94M
ABBV:
$17.96B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
GRC vs. ABBV — Risk / Return Rank
GRC
ABBV
GRC vs. ABBV - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for The Gorman-Rupp Company (GRC) and AbbVie Inc. (ABBV). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| GRC | ABBV | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +2.95 | ||
| Sortino ratioReturn per unit of downside risk | +3.59 | ||
| Omega ratioGain probability vs. loss probability | 1.59 | 1.18 | +0.41 |
| Calmar ratioReturn relative to maximum drawdown | 9.33 | 1.29 | +8.04 |
| Martin ratioReturn relative to average drawdown | 28.85 | 2.88 | +25.97 |
Loading charts...
Drawdowns
GRC vs. ABBV - Drawdown Comparison
The maximum GRC drawdown since its inception was -67.23%, which is greater than ABBV's maximum drawdown of -45.09%. Use the drawdown chart below to compare losses from any high point for GRC and ABBV.
Loading charts...
Drawdown Indicators
| GRC | ABBV | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -67.23% | -45.09% | -22.14% |
Max Drawdown (1Y)Largest decline over 1 year | -14.39% | -17.32% | +2.93% |
Max Drawdown (3Y)Largest decline over 3 years | -26.87% | -20.74% | -6.13% |
Max Drawdown (5Y)Largest decline over 5 years | -49.26% | -21.92% | -27.34% |
Max Drawdown (10Y)Largest decline over 10 years | -49.26% | -45.09% | -4.17% |
Current DrawdownCurrent decline from peak | 0.00% | -4.60% | +4.60% |
Average DrawdownAverage peak-to-trough decline | -17.63% | -10.71% | -6.92% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 4.67% | 7.75% | -3.08% |
Volatility
GRC vs. ABBV - Volatility Comparison
The Gorman-Rupp Company (GRC) has a higher volatility of 10.35% compared to AbbVie Inc. (ABBV) at 6.10%. This indicates that GRC's price experiences larger fluctuations and is considered to be riskier than ABBV based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| GRC | ABBV | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 10.35% | 6.10% | +4.25% |
Volatility (6M)Calculated over the trailing 6-month period | 28.10% | 17.85% | +10.25% |
Volatility (1Y)Calculated over the trailing 1-year period | 34.75% | 24.31% | +10.44% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 30.83% | 22.89% | +7.94% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 34.02% | 25.73% | +8.29% |
Dividends
GRC vs. ABBV - Dividend Comparison
GRC's dividend yield for the trailing twelve months is around 0.89%, less than ABBV's 2.96% yield.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
ABBV AbbVie Inc. | 2.96% | 2.87% | 3.49% | 3.82% | 3.49% | 3.84% | 4.41% | 4.83% | 3.89% | 2.65% | 3.64% | 3.41% |
GRC The Gorman-Rupp Company | 0.89% | 1.56% | 1.91% | 1.98% | 2.67% | 1.43% | 1.82% | 1.47% | 7.74% | 1.51% | 1.39% | 1.52% |
Financials
GRC vs. ABBV - Financials Comparison
This section allows you to compare key financial metrics between The Gorman-Rupp Company and AbbVie Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
GRC vs. ABBV - Profitability Comparison
GRC - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, The Gorman-Rupp Company reported a gross profit of 57.36M and revenue of 176.59M. Therefore, the gross margin over that period was 32.5%.
ABBV - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, AbbVie Inc. reported a gross profit of 12.53B and revenue of 15.00B. Therefore, the gross margin over that period was 83.5%.
GRC - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, The Gorman-Rupp Company reported an operating income of 27.48M and revenue of 176.59M, resulting in an operating margin of 15.6%.
ABBV - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, AbbVie Inc. reported an operating income of 4.73B and revenue of 15.00B, resulting in an operating margin of 31.6%.
GRC - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, The Gorman-Rupp Company reported a net income of 17.84M and revenue of 176.59M, resulting in a net margin of 10.1%.
ABBV - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, AbbVie Inc. reported a net income of 699.00M and revenue of 15.00B, resulting in a net margin of 4.7%.
Frequently Asked Questions
GRC and ABBV have a correlation of 0.19, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
GRC has higher volatility (10.35%) compared to ABBV (6.10%). In terms of maximum drawdown, GRC dropped -67.23% vs ABBV's -45.09%.
GRC currently has the higher Sharpe Ratio (3.87 vs 0.92), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for GRC and ABBV
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer